Tivozanib exhibits antitumor activity in renal cancer
The potent, selective vascular endothelial growth factor receptor-1, -2, and -3 inhibitor, tivozanib, demonstrates antitumor activity and is well tolerated in patients with advanced/metastatic renal cell carcinoma, according to research published online April 9 in the Journal of Clinical Oncology.
(HealthDay) -- The potent, selective vascular endothelial growth factor receptor-1, -2, and -3 inhibitor, tivozanib, demonstrates antitumor activity and is well tolerated in patients with advanced/metastatic renal cell carcinoma (RCC), according to research published online April 9 in the Journal of Clinical Oncology.
Dmitry A. Nosov, M.D., Ph.D., of the Blokhin Oncology Research Center in Moscow, and colleagues conducted a phase II randomized discontinuation trial (RDT) involving 272 patients with advanced or metastatic RCC to evaluate the antitumor activity and safety of tivozanib. Patients were given 1.5 mg/d orally for 16 weeks, where one cycle was defined as three treatment weeks followed by a one-week break. During the first open-label phase of the trial, patients who experienced 25 percent or more tumor shrinkage continued to take tivozanib, while those with less than 25 percent shrinkage progressed to the second 12-week, double-blind phase and were randomized to receive either tivozanib or placebo. If patients experienced 25 percent or more tumor growth, they were discontinued from the trial. Safety, objective response rate (ORR) at 16 weeks, and percentage of patients who were progression free after 12 weeks of double-blind treatment were primary end points, and progression-free survival was a secondary end point.
The researchers found that, overall, 83 percent of participants had tumors with clear-cell histology, 73 percent had undergone nephrectomy, and 54 percent were treatment naive. In the 16-week open-label phase, the ORR was 18 percent. Among the 118 patients randomized to treatment with tivozanib or placebo, a statistically significant between-group difference in the percentage of patients who remained progression free after 12 weeks was observed (49 and 21 percent, respectively). Grade 3 and 4 hypertension was the most common treatment-related adverse event.
"Results from this RDT demonstrated promising activity and an acceptable safety and tolerability profile for tivozanib in advanced/metastatic RCC," the authors write.
The study was supported by AVEO Pharmaceuticals; several authors disclosed financial relationships (including employment) with AVEO.
More information: Abstract
Full Text (subscription or payment may be required)
Journal reference: Journal of Clinical Oncology
Copyright © 2012 HealthDay. All rights reserved.
- Novel biomarker may predict response to new VEGF receptor inhibitor Sep 28, 2010 | not rated yet | 0
- Prophylaxis with apixaban feasible for cancer patients Mar 29, 2012 | not rated yet | 0
- Everolimus prolongs progression-free survival for patients with neuroendocrine tumors Nov 29, 2011 | not rated yet | 0
- Bevacizumab doesn't up overall survival in prostate cancer Mar 27, 2012 | not rated yet | 0
- Dual HER2 blockade significantly extends progression-free survival Dec 08, 2011 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Why is zone 1 in liver more prone to ischemic injury?
May 23, 2013 Hi, Is it because around central vein, there is only deoxygenated blood from the vein where as in the periphery there is hepatic artery. Also why...
How can there be villous adenoma in colon, if there are no villi there
May 22, 2013 As title suggest. Thanks :smile:
How can there be a term called "intestinal metaplasia" of stomach
May 21, 2013 Hello everyone, Ok Stomach's normal epithelium is simple columnar, now in intestinal type of adenocarcinoma of stomach it undergoes "intestinal...
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
- More from Physics Forums - Medical Sciences
More news stories
In recent years, microRNAs (miRNAs) and other non-coding RNAs are small molecules that help control the expression of specific proteins. In recent years they have emerged as disease biomarkers. miRNA profiles have been used ...
Cancer May 24, 2013 | not rated yet | 0
Cancer cells spread and grow by avoiding detection and destruction by the immune system. Stimulation of the immune system can help to eliminate cancer cells; however, there are many factors that cause the immune system to ...
Cancer May 24, 2013 | 5 / 5 (1) | 0
Researchers from London's Kingston University have begun a two-year study which could help prolong the lives of people with colorectal tumours.
Cancer May 24, 2013 | 5 / 5 (1) | 0
Transformative research from Western University has identified new hormones in the body which may suppress breast cancer and stimulate the regression of breast tumors.
Cancer May 24, 2013 | 5 / 5 (2) | 0
(Medical Xpress)—Curtin University researchers have found evidence that targeting specific cells in the body can reverse the effects of cancer on the immune system.
Cancer May 24, 2013 | 5 / 5 (4) | 0
Coenzyme Q10 decreases all cause mortality by half, according to the results of a multicentre randomised double blind trial presented today at Heart Failure 2013 congress. It is the first drug to improve heart failure mortality ...
21 hours ago | 5 / 5 (6) | 5
Heart failure accelerates the aging process and brings on early andropausal syndrome (AS), according to research presented today at the Heart Failure Congress 2013. AS, also referred to as male 'menopause', was four times ...
21 hours ago | 5 / 5 (1) | 1
(HealthDay)—Animals make great companions for senior citizens, but elderly people who always drive with a pet in the car are far more likely to crash than those who never drive with a pet, researchers have ...
13 hours ago | not rated yet | 1
(Medical Xpress)—A research team, led by Jeremy Barr, a biology post-doctoral fellow, unveils a new immune system that protects humans and animals from infection.
May 20, 2013 | 4.8 / 5 (31) | 9 |
Until now, little was scientifically known about the human potential to cultivate compassion—the emotional state of caring for people who are suffering in a way that motivates altruistic behavior.
May 22, 2013 | 4.3 / 5 (6) | 6 |
Mortality and length of stay are highest in heart failure patients admitted in January, on Friday, and overnight, according to research presented today at the Heart Failure Congress 2013. The analysis of nearly 1 million ...
21 hours ago | not rated yet | 0